| Early childhood development in Bangladesh and its socio-demographic determinants of importance MI Alam, M Mansur, P Barman Early Child Development and Care, 1-20, 2021 | 21 | 2021 |
| Combined criteria for dose optimisation in early phase clinical trials MI Alam, DS Coad, B Bogacka Statistics in Medicine 38 (21), 4172-4188, 2019 | 3 | 2019 |
| Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials MI Alam, B Bogacka, DS Coad Computational Statistics & Data Analysis 111, 183-202, 2017 | 3 | 2017 |
| Attitudes of Women Toward Domestic Violence: What Matters the Most? MI Alam, N Sultana Violence and Gender 9 (2), 87-95, 2022 | 2 | 2022 |
| On sample size calculation in testing treatment efficacy in clinical trials RJ Tamanna, MI Alam, A Hossain, MHR Khan Biometrical Letters 58 (2), 133-147, 2021 | 2 | 2021 |
| A comparison between the continual reassessment method and D-optimum design for dose finding in phase I clinical trials MI Alam Biometrical Letters 53 (2), 69-82, 2016 | 2 | 2016 |
| A dynamic stopping rule for phase I clinical trials MI Alam, M Mansur Biometrical Letters 55 (1), 17-30, 2018 | 1 | 2018 |
| Optimal adaptive designs for dose finding in early phase clinical trials MI Alam Queen Mary University of London, UK, 2015 | 1 | 2015 |
| Functional difficulty among young children in Bangladesh: An analysis of nationally representative data MM Rahman, MI Alam, M Mansur PloS one 19 (3), e0300403, 2024 | | 2024 |
| Prevalence and determinants of discrimination or harassment of women: analysis of cross-sectional data from Bangladesh Accepted for PLOS ONE, 2024 | | 2024 |
| Skilled birth attendants and caesarean sections: a case in Bangladesh MI Alam, N Sultana Journal of Public Health, 2023 | | 2023 |
| Patient-specific dose finding in seamless phase I/II clinical trials MI Alam, SI Shanto Sequential Analysis 41 (3), 367-386, 2022 | | 2022 |
| Stopping for efficacy in single-arm phase II clinical trials R Rahman, MI Alam Journal of Applied Statistics 49 (10), 2447-2466, 2022 | | 2022 |
| D-optimal designs for dose finding in phase I clinical trials HM Sujan, MI Alam Journal of Statistical Research 55 (2), 313-334, 2022 | | 2022 |
| Construction of windows for pharmacokinetic sampling MI Alam, N Sultana Austrian Journal of Statistics 50 (5), 23-37, 2021 | | 2021 |
| Early stopping in seamless phase I/II clinical trials NM Khan, MI Alam Pharmaceutical Statistics 20 (2), 390-412, 2020 | | 2020 |
| Isotonic design for phase I clinical trials: can we improve further? MI Alam, J Sultana Austrian Journal of Statistics 48, 34-44, 2019 | | 2019 |
| Assessing the inter-patient variability in the area under the concentration curve MI Alam Journal of Statistical Research 53 (1), 27-44, 2019 | | 2019 |
| Patient-specific dose finding in phase I clinical trials MM Moni, MI Alam Journal of Applied Statistics 45 (14), 2607-2618, 2018 | | 2018 |
| On performance of the 3+3 design and its modified versions for dose finding in phase I clinical trials MI Alam, MI Hossain Journal of Data Science 15 (1), 115-128, 2017 | | 2017 |
Mohaimen MansurAssociate Professor, University of DhakaVerified email at isrt.ac.bd
